Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Shares Outstanding (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Shares Outstanding for 4 consecutive years, with $56.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 48.81% to $56.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $56.5 million, a 48.81% increase, with the full-year FY2024 number at $38.2 million, up 6.76% from a year prior.
  • Shares Outstanding was $56.5 million for Q3 2025 at Orchestra BioMed Holdings, up from $38.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $56.5 million in Q3 2025 to a low of $10.1 million in Q1 2022.
  • A 4-year average of $33.8 million and a median of $35.8 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 1318.49% in 2023, then increased 0.23% in 2024.
  • Orchestra BioMed Holdings' Shares Outstanding stood at $2.5 million in 2022, then surged by 1318.49% to $35.8 million in 2023, then rose by 6.76% to $38.2 million in 2024, then soared by 47.83% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Shares Outstanding are $56.5 million (Q3 2025), $38.6 million (Q2 2025), and $38.3 million (Q1 2025).